4.7 Review

Novel nanomedicines to overcome cancer multidrug resistance

期刊

DRUG RESISTANCE UPDATES
卷 58, 期 -, 页码 -

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2021.100777

关键词

Cancer; Antitumor drugs; Drug resistance; MDR; P-gp; ABCB1; Nanomedicine

资金

  1. Guangdong Basic and Applied Basic Research Foundation [2020B1515120032]
  2. Guang-dong Basic and Applied Basic Research fund project [2019B1515120033]
  3. Science and Technology Foundation of Shenzhen [JCYJ20180305164128430]
  4. International Cooperation Foundation of Shenzhen [GJHZ20180928171602104]
  5. Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis
  6. Shenzhen Economic and Information Committee Innovation Chain and Industry Chain integration special support plan project [20180225112449943]
  7. Shenzhen Key Medical Discipline Construction Fund [SZXK053]

向作者/读者索取更多资源

Chemotherapy is powerful in eliminating malignant cells, but its efficacy is often hindered by drug resistance. Nanomedicine, focusing on targeted drug delivery to tumor tissues using nano-sized formulations, shows promise in improving treatment outcomes, minimizing adverse effects, and overcoming cancer drug resistance. This approach involves strategies such as passive and active targeted delivery, delivering multidrug combinations, and multimodal combination therapy to pave the way for effective cancer treatment and holds great potential in overcoming drug resistance.
Chemotherapy remains a powerful tool to eliminate malignant cells. However, the efficacy of chemotherapy is compromised by the frequent emergence of intrinsic and acquired multidrug resistance (MDR). These chemoresistance modalities are based on a multiplicity of molecular mechanisms of drug resistance, including : 1) Impaired drug uptake into cancer cells; 2) Increased expression of ATP-binding cassette efflux transporters; 3) Loss of function of pro-apoptotic factors; 4) Enhanced DNA repair capacity; 5) Qualitative or quantitative alterations of specific cellular targets; 6) Alterations that allow cancer cells to tolerate adverse or stressful conditions; 7) Increased biotransformation or metabolism of anticancer drugs to less active or completely inactive metabolites; and 8) Intracellular and intercellular drug sequestration in well-defined organelles away from the cellular target. Hence, one of the major aims of cancer research is to develop novel strategies to overcome cancer drug resistance. Over the last decades, nanomedicine, which focuses on targeted delivery of therapeutic drugs into tumor tissues using nano-sized formulations, has emerged as a promising tool for cancer treatment. Therefore, nanomedicine has been introduced as a reliable approach to improve treatment efficacy and minimize detrimental adverse effects as well as overcome cancer drug resistance. With rationally designed strategies including passively targeted delivery, actively targeted delivery, delivery of multidrug combinations, as well as multimodal combination therapy, nanomedicine paves the way towards efficacious cancer treatment and hold great promise in overcoming cancer drug resistance. Herein, we review the recent progress of nanomaterials used in medicine, including liposomal nanoparticles, polymeric nanoparticles, inorganic nanoparticles and hybrid nanoparticles, to surmount cancer multidrug resistance. Finally, the future perspectives of the application of nanomedicine to reverse cancer drug resistance will be addressed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据